Researchers have found a way to rejuvenate the glycocalyx, the “sugar shield” that bolsters the blood-brain barrier. Exciting ...

DelveInsight's,“ Thyroid Cancer Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 51+ ...

Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced three leadership appointments. Brian Gorman joins Hansa as Chief Legal Officer ...

Discover the current challenges in diagnosing multiple myeloma and how advances in diagnostic technologies could help ...

Another possibility is that there is something in the tick saliva that promotes immunoglobulin class switching, whereby B cells change their production of immunoglobulin from one class to another, ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

This study provides valuable findings regarding potential correlates of protection against the African swine fever virus. The evidence supporting the claims is solid, although analysis using a higher ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine ...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease 56% of Patients with Low Tau ...